NDA 202811 · Abbvie
Linzess
Linaclotide · Oral · Guanylate Cyclase-C Agonist
NovelLast checked: Nov 19, 2026Latest source record: May 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Aug 30, 2012
Approved uses
6
Original approval plus efficacy supplements
Registered trials
53
16 Phase 3, 1 recruiting
FAERS reports
27,305
9,962 serious, 1,100 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE LINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.4 )]. WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE See full prescribing information for complete boxed warning. LINZESS is contraindicated in patients less than 2 years of age; in neonatal mice, linaclotide caused deaths due to dehydration. ( 4 , 5.1 , 8.4 )
What it is approved for
From the label in effect Oct 10, 2026.
LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 2 years of age and older LINZESS is a guanylate cyclase-C agonist indicated for treatment of: Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older. ( 1 ) Chronic idiopathic constipation (CIC) in adults. ( 1 ) Functional constipation (FC) in pediatric patients 2 years of age and older. ( 1 )
Mechanism: Linaclotide is structurally related to human guanylin and uroguanylin and functions as a guanylate cyclase-C (GC-C) agonist. Both linaclotide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 21, 2026 Supplement 23 · Efficacy · priority review LabelLetter
- Nov 4, 2025 Supplement 22 · Efficacy · priority review LabelMedication GuideLetter
- Jun 12, 2023 Supplement 21 · Efficacy · priority review LetterLabelMedication Guide
- Sep 22, 2020 Supplement 16 · Efficacy LetterLabel
- Jan 25, 2017 Supplement 10 · Efficacy LabelLetterReview
- Aug 30, 2012 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewLabel
3 products under this application
- LINZESS · LINACLOTIDE 72MCG · CAPSULE, ORAL · Prescription · TE AB
- LINZESS · LINACLOTIDE 145MCG · CAPSULE, ORAL · Prescription · TE AB
- LINZESS · LINACLOTIDE 290MCG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Linaclotide" as an intervention, any sponsor and status, largest first.
- An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationPivotal-lookingCompleted
Ironwood Pharmaceuticals, Inc.Industry
NCT00730171 · 1,743 participants · Start Sep 2008 · Primary completion Mar 2012
Drug: Linaclotide · For: Irritable Bowel Syndrome With Constipation; Chronic Constipation
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 116 sites in all
AstraZenecaAstraZeneca (AZN)
NCT01880424 · 1,722 participants · Start Jul 2013 · Primary completion May 2015
Drug: Placebo; Linaclotide · For: Irritable Bowel Syndrome With Constipation (IBS-C)
Sites: Huntsville, Alabama; North Little Rock, Arkansas; Phoenix, Arkansas · 82 sites in all
- Application of Linaclotide Capsule in Bowel Preparation for ColonoscopyPivotal-lookingCompleted
Changhai HospitalAcademic, hospital or other
NCT05291325 · 1,607 participants · Start May 25, 2022 · Primary completion Aug 30, 2023
Drug: 3L PEG + Linaclotide; 3L PEG and 1 more · For: Bowel Preparation for Colonoscopy
Sites: Shanghai, China
- An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00765999 · 1,559 participants · Start Oct 31, 2008 · Primary completion Jan 31, 2012
Drug: Linaclotide · For: Chronic Constipation; Irritable Bowel Syndrome With Constipation
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 118 sites in all
- Trial of Linaclotide in Patients With Chronic Idiopathic ConstipationPivotal-lookingCompleted
Ironwood Pharmaceuticals, Inc.Industry
NCT02291679 · 1,223 participants · Start Oct 2014 · Primary completion Aug 2015
Drug: Linaclotide; Matching Placebo · For: Chronic Idiopathic Constipation
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 95 sites in all
- An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic ConstipationPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT02590432 · 828 participants · Start Nov 1, 2015 · Primary completion Feb 5, 2018
Drug: Linaclotide · For: Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation
Sites: Anniston, Alabama; Athens, Alabama; Childersburg, Alabama · 79 sites in all
- Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Pivotal-lookingCompleted
Ironwood Pharmaceuticals, Inc.Industry
NCT00938717 · 805 participants · Start Jul 2009 · Primary completion Sep 2010
Drug: Linaclotide or Matching Placebo · For: Irritable Bowel Syndrome With Constipation
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 107 sites in all
- Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With ConstipationPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00948818 · 803 participants · Start Jul 2009 · Primary completion Jul 2010
Drug: Linaclotide 290 micrograms; Matching placebo · For: Irritable Bowel Syndrome Characterized by Constipation
Sites: Birmingham, Alabama; Hueytown, Alabama; Huntsville, Alabama · 118 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea4,777
- drug ineffective4,586
- off label use3,406
- constipation2,071
- nausea1,522
- fatigue1,213
- abdominal distension1,188
- abdominal pain1,089
- headache1,073
- pain991
- abdominal pain upper969
- dizziness879
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 9 |
| 2013 | 597 |
| 2014 | 1,295 |
| 2015 | 1,290 |
| 2016 | 2,129 |
| 2017 | 2,256 |
| 2018 | 2,579 |
| 2019 | 2,374 |
| 2020 | 2,225 |
| 2021 | 1,937 |
| 2022 | 1,882 |
| 2023 | 1,994 |
| 2024 | 2,049 |
| 2025 | 2,478 |
| 2026 | 2,211 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Linzess (Linaclotide)
2024 spending
$1.98B
Beneficiaries
632,063
2,506,531 claims
Per beneficiary
$3,136
$17.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,144,468,128 |
| 2021 | $1,374,354,961 |
| 2022 | $1,581,669,987 |
| 2023 | $1,825,245,843 |
| 2024 | $1,981,958,629 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
Luthra P, Camilleri M, Burr NE, et al. · Lancet Gastroenterol Hepatol 2019 · Research Support, N.I.H., Extramural, Systematic Review
- Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm.
Rao SS, Manabe N, Karasawa Y, et al. · BMC Gastroenterol 2024 · Comparative Study, Meta-Analysis
- Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al. · Lancet Gastroenterol Hepatol 2024 · Randomized Controlled Trial, Multicenter Study
- Pharmacological treatment for antipsychotic-related constipation.
Every-Palmer S, Newton-Howes G, Clarke MJ · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysis.
de Geus A, Gordon M, Sinopoulou V, et al. · Lancet Child Adolesc Health 2025 · Systematic Review, Meta-Analysis
- Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in China.
Xiao D, Zhang Y, Chen W, et al. · Adv Ther 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.